| Zohreh T Farahbakhsh, RPH, PHD | |
|
4710 Commons Way, Calabasas, CA 91302-3364 | |
| (818) 222-0549 | |
| (818) 222-0665 |
| Full Name | Zohreh T Farahbakhsh |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 4710 Commons Way, Calabasas, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265752307 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 50110 (California) | Primary |
| 183500000X | Pharmacist | 14502 (Nevada) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Zohreh T Farahbakhsh, RPH, PHD 4710 Commons Way, Calabasas, CA 91302-3364 Ph: (818) 222-0549 | Zohreh T Farahbakhsh, RPH, PHD 4710 Commons Way, Calabasas, CA 91302-3364 Ph: (818) 222-0549 |
News Archive
During the five years before people develop the first clinically recognized signs of multiple sclerosis, they are up to four times more likely to be treated for nervous system disorders such as pain or sleep problems, and are 50 per cent more likely to visit a psychiatrist, according to new research from the University of British Columbia.
Helicos BioSciences Corporation a life science company focused on innovative genetic analysis technologies, today announced the publication of a landmark study in which Helicos' True Single Molecule Sequencing (tSMS)™ technology was used to directly sequence individual molecules of RNA. The paper appeared yesterday in the on-line edition of Nature and will appear in an upcoming 2009 print issue of Nature.
Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.
Semler Scientific, Inc., an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
› Verified 5 days ago
Dr. Peter S Golenia, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4651 Camino Del Sol, Calabasas, CA 91302 Phone: 702-280-7544 | |
Ferial Khorassani-farrokhi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 23693 Calabasas Rd, Calabasas, CA 91302 Phone: 818-403-3072 | |
Linda Lin, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 26521 Agoura Rd, Calabasas, CA 91302 Phone: 818-880-8692 Fax: 818-880-8927 | |
Juliana Avakeretyan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 22277 Mulholland Hwy, Calabasas, CA 91302 Phone: 818-231-7823 | |
Mrs. Valerie Anne Mesaros, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 26830 Hot Springs Pl, Calabasas, CA 91301 Phone: 818-914-6085 | |
Leslie Ziontz, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5733 Las Virgenes Rd Ste A, Calabasas, CA 91302 Phone: 818-456-4274 Fax: 818-456-4273 |